Liangjun Zhu
Overview
Explore the profile of Liangjun Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
498
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ding Y, Feng Y, Ye Y, Shen J, Guo C, He X, et al.
Front Oncol
. 2025 Feb;
15:1503517.
PMID: 39980556
Introduction: Microsatellite stable (MSS) colorectal cancer with liver metastases (CLRM) responds poorly to immunotherapy, and various approaches to break immune tolerance have been tried. Radiotherapy in combination with immune checkpoint...
2.
Tang Z, Zheng X, Pan J, Huang X, Zhu L, Wang N, et al.
Sci Total Environ
. 2025 Jan;
963():178545.
PMID: 39827630
To comprehensively assess regional landslide hazards, we propose a geospatial approach that jointly evaluates both the probability of occurrence (susceptibility) and potential destructive power (intensity) within a single framework, overcoming...
3.
Li S, Li X, Xu H, Huang J, Zhu J, Peng Y, et al.
Signal Transduct Target Ther
. 2024 Dec;
9(1):346.
PMID: 39658608
Previous studies showed encouraging efficacy of alternating FOLFOX/FOLFIRI for metastatic colorectal cancer (mCRC). This phase 2 trial (NCT04324476) aimed to evaluate efficacy and safety of alternating modified CAPOX (capecitabine and...
4.
Li S, Li X, Zhu Q, Gao J, Zhu C, Zhu L
Cancer Control
. 2024 Sep;
31:10732748241275012.
PMID: 39286935
Objectives: Clinical studies have shown that bevacizumab plus chemotherapy significantly improves efficacy in metastatic colorectal cancer (mCRC). This prospective study aims to investigate the efficacy and safety of changing second-line...
5.
Liu Y, Sun D, Huang Y, Shen Y, Chen T, Chen W, et al.
Front Pharmacol
. 2024 Aug;
15:1435889.
PMID: 39211779
Retinoic acid is an active metabolite with significant physiological functions in human development, immunity, vision, and skin health. In recent years, research on retinoic acid in the field of kidney...
6.
Tang W, Liu S, Jing M, Healey J, Smith M, Farooq T, et al.
Glob Chang Biol
. 2024 Jul;
30(7):e17441.
PMID: 39054867
Vegetation growth is affected by past growth rates and climate variability. However, the impacts of vegetation growth carryover (VGC; biotic) and lagged climatic effects (LCE; abiotic) on tree stem radial...
7.
Qin S, Li J, Zhou A, Zhang Y, Yuan X, Zhu L, et al.
Cancer Commun (Lond)
. 2024 Jul;
44(8):910-914.
PMID: 38976318
No abstract available.
8.
Li J, Wang Z, Zhong H, He Y, Zhang C, Niu Z, et al.
Oncologist
. 2024 Apr;
29(8):e1012-e1019.
PMID: 38642091
Introduction: Fruquintinib is approved in China for patients with metastatic colorectal cancer (CRC) who progressed after 2 lines of chemotherapy. This postmarketing study was conducted to evaluate the safety of...
9.
Qu W, Liu Z, Chen X, Liu B, Zhao Y, Yan H, et al.
BMC Cancer
. 2024 Jan;
24(1):22.
PMID: 38166647
Objective: To evaluate the efficacy and safety of regorafenib monotherapy or in combination with immune-checkpoint inhibitor while treating Chinese patients with metastatic colorectal cancer (mCRC): a real-world study. Methods: The...
10.
Li S, Bao J, Li X, Yang Q, Xu J, Chen S, et al.
EClinicalMedicine
. 2023 Nov;
66:102314.
PMID: 38024480
Background: Pembrolizumab plus trastuzumab and chemotherapy showed remarkable efficacy as first-line therapy for advanced HER2-positive gastric cancer. Pyrotinib is an irreversible pan-HER inhibitor. This single-arm, open-label phase 1 dose-escalation (1a)...